Pulse Biosciences, Inc. (PLSE) stock
PLSENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$44.84−1.52 (-3.28%)
Close on Nov 17, 2026Market cap $3.20BP/E –Yield –
Pulse Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Pulse Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $51.89M, up 27.3% year over year. For fiscal 2025 it was $44.72M, up 38.3% from the year before. Over ten years it grew 35.3% a year on average. The highest annual figure on record is $44.72M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.72M | +38.3% |
| FY2024 | Dec 31, 2024 | $32.34M | +16.3% |
| FY2023 | Dec 31, 2023 | $27.80M | +33.4% |
| FY2022 | Dec 31, 2022 | $20.84M | -27.2% |
| FY2021 | Dec 31, 2021 | $28.64M | +8.3% |
| FY2020 | Dec 31, 2020 | $26.44M | +5.9% |
| FY2019 | Dec 31, 2019 | $24.96M | +44.7% |
| FY2018 | Dec 31, 2018 | $17.25M | +78.9% |
| FY2017 | Dec 31, 2017 | $9.65M | +75.2% |
| FY2016 | Dec 31, 2016 | $5.51M | +152.5% |
| FY2015 | Dec 31, 2015 | $2.18M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $16.98M | +40.4% |
| Q1 FY2026 | Mar 31, 2026 | $12.59M | +22.1% |
| Q4 FY2025 | Dec 31, 2025 | $10.93M | +2.5% |
| Q3 FY2025 | Sep 30, 2025 | $11.39M | +47.9% |
| Q2 FY2025 | Jun 30, 2025 | $12.09M | +67.2% |
| Q1 FY2025 | Mar 31, 2025 | $10.31M | +53.0% |
| Q4 FY2024 | Dec 31, 2024 | $10.66M | +36.7% |
| Q3 FY2024 | Sep 30, 2024 | $7.70M | +3.1% |
| Q2 FY2024 | Jun 30, 2024 | $7.23M | +8.0% |
| Q1 FY2024 | Mar 31, 2024 | $6.74M | +15.6% |
| Q4 FY2023 | Dec 31, 2023 | $7.80M | +90.5% |
| Q3 FY2023 | Sep 30, 2023 | $7.47M | +65.4% |
| Q2 FY2023 | Jun 30, 2023 | $6.70M | +22.7% |
| Q1 FY2023 | Mar 31, 2023 | $5.83M | -13.9% |
| Q4 FY2022 | Dec 31, 2022 | $4.10M | -27.6% |
| Q3 FY2022 | Sep 30, 2022 | $4.52M | -30.1% |
| Q2 FY2022 | Jun 30, 2022 | $5.46M | -26.8% |
| Q1 FY2022 | Mar 31, 2022 | $6.77M | -25.3% |
| Q4 FY2021 | Dec 31, 2021 | $5.66M | -23.8% |
| Q3 FY2021 | Sep 30, 2021 | $6.46M | -7.3% |
| Q2 FY2021 | Jun 30, 2021 | $7.46M | +27.1% |
| Q1 FY2021 | Mar 31, 2021 | $9.06M | +46.6% |
| Q4 FY2020 | Dec 31, 2020 | $7.43M | +12.7% |
| Q3 FY2020 | Sep 30, 2020 | $6.97M | +12.5% |
| Q2 FY2020 | Jun 30, 2020 | $5.87M | -7.4% |
| Q1 FY2020 | Mar 31, 2020 | $6.18M | +5.8% |
| Q4 FY2019 | Dec 31, 2019 | $6.59M | +29.7% |
| Q3 FY2019 | Sep 30, 2019 | $6.19M | +22.9% |
| Q2 FY2019 | Jun 30, 2019 | $6.34M | +60.0% |
| Q1 FY2019 | Mar 31, 2019 | $5.84M | +84.0% |
| Q4 FY2018 | Dec 31, 2018 | $5.08M | +77.4% |
| Q3 FY2018 | Sep 30, 2018 | $5.04M | +72.2% |
| Q2 FY2018 | Jun 30, 2018 | $3.96M | +85.9% |
| Q1 FY2018 | Mar 31, 2018 | $3.18M | +83.8% |
| Q4 FY2017 | Dec 31, 2017 | $2.86M | +73.7% |
| Q3 FY2017 | Sep 30, 2017 | $2.93M | +88.3% |
| Q2 FY2017 | Jun 30, 2017 | $2.13M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.73M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.65M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.55M | – |
See a number that looks wrong?